专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008148018A2 RAPIDLY DISPERSIBLE VAGINAL TABLET THAT PROVIDES A BIOADHESIVE GEL 审中-公开
标题翻译：提供生物凝胶的快速不平的血管片
公开(公告)号：WO2008148018A2
公开(公告)日：2008-12-04
申请号：PCT/US2008064737
申请日：2008-05-23
申请人： NEW YORK BLOOD CT INC , STONE ALAN , NEURATH ALEXANDER ROBERT , STRICK NATHAN , JIANG SHIBO
发明人： STONE ALAN , NEURATH ALEXANDER ROBERT , STRICK NATHAN , JIANG SHIBO
IPC分类号： A61K9/20
CPC分类号： A61K9/0034 , A61K9/2018 , A61K31/00
摘要： A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2- benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV- 1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.
摘要翻译：用于插入阴道的片剂，其包含0.01至500mg的阴道药物，例如杀微生物剂，例如1,2-乙二羧酸纤维素酯（CAP）; 100〜500mg甘露糖醇粉末; 50〜300mg惰性微晶纤维素; 10至80mg羟丙基甲基纤维素; 50至250mg的甘油和任选的2至4mg的至少一种防腐剂，其防止杀微生物污染并阻止酵母在阴道中的生长。包括CAP作为阴道药物的片剂在防止HIV-1，HIV-2，疱疹病毒的性传播或由淋病奈瑟氏球菌，沙眼衣原体，阴道毛滴虫，杜氏乳杆菌或密螺旋体感染引起的感染的方法之前阴道给药梅毒螺旋体。包括CAP作为阴道药物的片剂被阴道施用以预防或治疗细菌性阴道病。

2. 发明公开

EP1030547A4 METHODS FOR PREVENTING AND TREATING BACTERIAL INFECTIONS USING CELLULOSE ACETATE PHTHALATE OR HYDROXYPROPYL METHYLCELLULOSE PHTHALATE EXCIPIENTS 有权
标题翻译：方法预防和治疗中使用或CELLULOSEACETATPHTHALAT-HYDROXYPROPPYLMETHYLCELLULOSETRÄGERSTOFFEN细菌感染
公开(公告)号：EP1030547A4
公开(公告)日：2002-11-06
申请号：EP98956122
申请日：1998-10-21
申请人： NEW YORK BLOOD CT INC , NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON J
发明人： NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON JAY
IPC分类号： A61K9/06 , A61K9/107 , A61K9/14 , A61K31/717 , A61K47/02 , A61K47/10 , A61K47/32 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A01F25/02 , A01F25/08 , A61K31/715
CPC分类号： A61K9/14 , A61K31/717

3. 发明专利

DE69828196T2 未知
公开(公告)号：DE69828196T2
公开(公告)日：2006-02-23
申请号：DE69828196
申请日：1998-10-21
申请人： NEW YORK BLOOD CT INC , NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON J
发明人： NEURATH ROBERT , JIANG SHIBO , DEBNATH KUMAR , STRICK NATHAN , DOW JAY
IPC分类号： A61K9/06 , A61K9/107 , A61K9/14 , A61K31/715 , A61K31/717 , A61K47/02 , A61K47/10 , A61K47/32 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22
摘要： A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

4. 发明专利

DE69828196D1 未知
公开(公告)号：DE69828196D1
公开(公告)日：2005-01-20
申请号：DE69828196
申请日：1998-10-21
申请人： NEW YORK BLOOD CT INC , NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON J
发明人： NEURATH ROBERT , JIANG SHIBO , DEBNATH KUMAR , STRICK NATHAN , DOW JAY
IPC分类号： A61K9/06 , A61K9/107 , A61K9/14 , A61K31/717 , A61K47/02 , A61K47/10 , A61K47/32 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61K31/715
摘要： A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

5. 发明专利

AT284675T 未知
公开(公告)号：AT284675T
公开(公告)日：2005-01-15
申请号：AT98956122
申请日：1998-10-21
申请人： NEW YORK BLOOD CT INC , NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON J
发明人： NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON JAY
IPC分类号： A61K9/06 , A61K9/107 , A61K9/14 , A61K31/717 , A61K47/02 , A61K47/10 , A61K47/32 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61K31/715
摘要： A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

6. 发明专利

AU1271799A Methods for preventing and treating bacterial infections using cellulose acetatephthalate or hydroxypropyl methylcellulose phthalate excipients 未知
公开(公告)号：AU1271799A
公开(公告)日：1999-05-10
申请号：AU1271799
申请日：1998-10-21
申请人： DEBNATH ASIM KUMAR , DOW GORDON JAY , JIANG SHIBO , NEURATH ALEXANDER ROBERT , NEW YORK BLOOD CENTER INC , STRICK NATHAN
发明人： NEURATH ALEXANDER ROBERT , JIANG SHIBO , DEBNATH ASIM KUMAR , STRICK NATHAN , DOW GORDON JAY
IPC分类号： A61K9/06 , A61K9/107 , A61K9/14 , A61K31/717 , A61K47/02 , A61K47/10 , A61K47/32 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A01F25/02 , A01F25/08
摘要： A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

7. 发明申请

WO2004047730A2 COMPOUNDS FOR INHIBITION OF HIV INFECTION BY BLOCKING HIV ENTRY 审中-公开
标题翻译：通过阻止艾滋病毒入侵来抑制艾滋病毒感染的化合物
公开(公告)号：WO2004047730A2
公开(公告)日：2004-06-10
申请号：PCT/US0336359
申请日：2003-11-12
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , DEBNATH ASIM KUMAR
发明人： JIANG SHIBO , DEBNATH ASIM KUMAR
IPC分类号： A61K20060101 , A61K31/40 , C07D207/30 , C07D207/32 , C07D207/327 , C07D413/04 , C07D417/04 , A61K
CPC分类号： C07D207/327
摘要： A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with IC50 values
摘要翻译：鉴定了一组通过阻断HIV进入而抑制HIV复制的化合物。两种代表性的化合物（称为NB-2和NB-64）抑制HIV复制（p24产生），IC50值<0.5 mug / ml。证明NB-2和NB-64是通过靶向HIV gp41的HIV进入抑制因子，因为：1）它们抑制HIV介导的细胞融合; 2）只有当病毒加入不到1小时后，才能抑制HIV复制; 3）它们不阻断gp120-CD4结合; 4）它们没有与共受体CXCR4相互作用，因为它们不能阻断抗CXCR4抗体结合CXCR4表达细胞; 5）它们阻断了使用构象特异性Mab NC-1通过夹心酶联免疫吸附测定（ELISA）检测到的gp41核心的形成; 6）它们抑制荧光天然 - 聚丙烯酰胺凝胶电泳（FN-PAGE）显示的gp41六螺旋束的形成; 和7）它们阻断了肽肽与肽IQN17模拟的gp41卷曲螺旋结构域内的疏水空穴的结合。这些结果表明NB-2和NB-64可能与疏水腔相互作用并阻断融合活性gp41卷曲螺旋结构域的形成，导致HIV-1介导的膜融合和病毒进入的抑制。

8. 发明申请

WO2010091373A3 TRIMERICH HIV FUSION INHIBITORS FOR TREATING OR PREVENTING HIV INFECTION 审中-公开
标题翻译： TRIMERICH艾滋病毒融合抑制剂治疗或预防艾滋病毒感染
公开(公告)号：WO2010091373A3
公开(公告)日：2010-09-30
申请号：PCT/US2010023522
申请日：2010-02-08
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
发明人： JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
IPC分类号： A61K38/17 , A61P31/18
CPC分类号： A61K38/162 , A61K38/00 , C07K14/005 , C07K2319/735 , C12N7/00 , C12N2740/16022 , C12N2740/16033 , C12N2740/16111 , C12N2740/16122
摘要： Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1 ) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
摘要翻译：本文公开了包含三种单体的三聚体多肽药物组合物，每种单体包含具有人类跨膜糖蛋白的N-末端七肽重复（NHR或HR1）或C-末端七重复重复（CHR或HR2）的氨基酸序列的多肽免疫缺陷病毒（HIV）和三聚体基序。

9. 发明申请

WO2005120565A8 SARS VACCINES AND METHODS TO PRODUCE HIGHLY POTENT ANTIBODIES 审中-公开
标题翻译： SARS疫苗和生产高度抗体的方法
公开(公告)号：WO2005120565A8
公开(公告)日：2006-02-09
申请号：PCT/US2005019266
申请日：2005-06-01
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , HE YUXIAN , LIU SHUWEN
发明人： JIANG SHIBO , HE YUXIAN , LIU SHUWEN
IPC分类号： A61K39/00 , A61K39/215 , C07K14/165
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/30 , C12N2770/20022
摘要： This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.
摘要翻译：本发明提供一种疫苗，其包含有效量的分离的多肽或重组蛋白，其含有SARS相关冠状病毒穗状蛋白或其功能片段中受体结合结构域的序列，或包含该片段的序列的核酸分子编码重症急性呼吸综合征相关冠状病毒穗蛋白或其功能片段中受体结合结构域的序列。本发明提供用于增加抗原的免疫原性的组合物，其包含有效量的抗原和IgG Fc结构域，其功能片段或含有IgG Fc结构域或其功能片段的物质。抗原和IgG Fc可以连接或未连接。最后，本发明还提供了使用任何上述组合物进行免疫的方法。

10. 发明申请

WO2006138118B1 ANTI-VIRAL COMPOSITIONS COMPRISING HETEROCYCLIC SUBSTITUTED PHENYL FURANS AND RELATED COMPOUNDS 审中-公开
标题翻译：包含杂环取代苯基呋喃的抗病毒组合物及相关化合物
公开(公告)号：WO2006138118B1
公开(公告)日：2007-09-20
申请号：PCT/US2006021993
申请日：2006-06-06
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , DEBNATH ASIM KUMAR , LU HONG
发明人： JIANG SHIBO , DEBNATH ASIM KUMAR , LU HONG
IPC分类号： A61K31/53 , A61K31/427 , A61K31/4439 , A61K31/496 , A61K31/497 , A61K31/501
CPC分类号： A61K31/427 , A61K31/4439 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/53
摘要： A group of compounds that inhibit HIV replication by blocking HIV entry was identified. One representative compound, designated NB-206, and its analogs inhibited HIV replication (p24 production) with IC50 values at nanomolar levels. It was proved that NB-206 and its analogs are HIV entry inhibitors by targeting the HIV gp41 since: 1) they inhibited HIV-mediated cell fusion; 2) they inhibited HIV replication only when they were added to the cells less than one hour after virus addition; 3) they blocked the formation of the gp41 core that is detected by sandwich enzyme linked immunosorbent assay (ELISA) using a conformation- specific MAb NC-I; and 4) they inhibited the formation of the gp41 six-helix bundle revealed by fluorescence native-polyacrylamide gel electrophoresis (FN-PAGE) . These results suggested that NB-206 and its analogs may interact with the hydrophobic cavity and block the formation of the fusion- active gp41 coiled coil domain, resulting in inhibition of HIV-I mediated membrane fusion and virus entry.
摘要翻译：确定了一组通过阻止HIV进入来抑制HIV复制的化合物。一种名为NB-206的代表性化合物及其类似物抑制HIV复制（p24产生），IC 50值在纳摩尔水平。已经证明NB-206及其类似物是通过靶向HIV gp41的HIV进入抑制剂，因为：1）它们抑制HIV介导的细胞融合; 2）只有当病毒添加后不到1小时才加入到细胞中时，它们就抑制HIV复制; 3）它们阻断了使用构象特异性MAb NC-1通过夹心酶联免疫吸附测定（ELISA）检测到的gp41核心的形成; 和4）它们抑制荧光天然聚丙烯酰胺凝胶电泳（FN-PAGE）显示的gp41六螺旋束的形成。这些结果表明NB-206及其类似物可能与疏水空腔相互作用并阻断融合活性gp41卷曲螺旋结构域的形成，导致抑制HIV-1介导的膜融合和病毒进入。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式